Thursday, December 18, 2014 Last update: 6:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

BIND Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014

Companies mentioned in this article: BIND Therapeutics, Inc.

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced it will report second quarter 2014 financial results on Thursday, August 7, 2014. BIND’s management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time on Thursday, August 7, 2014 to discuss the quarterly results and recent business developments.

To access the conference call, please dial (877) 312-5844 (domestic) or (253) 237-1152 (international) at least five minutes prior to the start time and refer to conference ID 78041099. A live audio webcast of the call will also be available on the Investors & Media section of the company's website, www.bindtherapeutics.com. An archived webcast will be available on the Company’s website approximately two hours after the event.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer and metastatic castrate-resistant prostate cancer.

BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB and F. Hoffmann-La Roche Ltd. to develop Accurins based on their proprietary therapeutic payloads and targeting ligands.. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the Company's web site at www.bindtherapeutics.com.


Copyright © Business Wire 2014
Contact:

Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com
or
Investors:
Stern Investor Relations
Paul Cox, 212-362-1200
paul@sternir.com